LBA43 Intradermal IMO-2125 versus placebo as adjuvant treatment in patients with stage II pT3-4/cN0 melanoma: Interim efficacy and safety results of the randomized phase II INTRIM study.
Saved in:
| Title: | LBA43 Intradermal IMO-2125 versus placebo as adjuvant treatment in patients with stage II pT3-4/cN0 melanoma: Interim efficacy and safety results of the randomized phase II INTRIM study. |
|---|---|
| Authors: | Notohardjo, J.C.L.1 (AUTHOR), Veenstra, S.1 (AUTHOR), Koster, B.D.1 (AUTHOR), Kandiah, V.1 (AUTHOR), van der Velde, S.2 (AUTHOR), Francken, A.B.3 (AUTHOR), Gooiker, G.A.4 (AUTHOR), van den Tol, M.P.2 (AUTHOR), Bekkenk, M.W.5 (AUTHOR), Hof, K.H. in 't6 (AUTHOR), Straver, M.E.7 (AUTHOR), Molenkamp, B.G.8 (AUTHOR), Vuylsteke, R.J.C.L.M.9 (AUTHOR), Lissenberg-Witte, B.I.10 (AUTHOR), Labots, M.1 (AUTHOR), Chunduru, S.K.11 (AUTHOR), van Akkooi, A.C.J.12 (AUTHOR), Van Den Eertwegh, F.1 (AUTHOR), de Gruijl, T.D.1 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1410-S1410. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.08.042 |
